CAS: 61263-35-2; Meteneprost

该化合物是合成的蛋白质类比,在药物研发中具有显著应用,其主要优势在于其结构与天然的蛋白质相似,能够有针对性地进行生物活动,特别是在肌肉肌肉平稳收缩和宫颈成熟方面.Metenerprost展示了高能性和选择性,使其成为研究子宫生理学和开发妇科病治疗剂的宝贵化合物.它的稳定性和可预测的药用动因特征进一步增强了其在临床前和临床环境中的效用.研究人员认为,Metenerenprest在调节孕育性中间途径方面具有再生性和有效性,支持生殖健康和相关医疗干预的进步.

结构式图片

合成工艺路线路线简述

    海关参考信息

    专利信息


    专利号:US-7772278-B2
    优先权日:1999-03-01
    标 题:Nitrosated and nitrosylated prostaglandins, compositions and methods of use
    发明人:GARVEY DAVID S; GASTON RICKY D; LETTS L GORDON; DE TEJADA INIGO SAENZ; TAM SANG WILLIAM; WORCEL MANUEL
    权利人:NITROMED INC
    摘要:The invention describes novel nitrosated and/or nitrosylated prostaglandins, and novel compositions comprising at least one nitrosated and/or nitrosylated prostaglandin, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase, and/or at least one vasoactive agent. The invention also provides novel compositions comprising at least one prostaglandin and at least one S-nitrosothiol compound, and, optionally, at least one vasoactive agent. The prostaglandin is preferably a prostaglandin E 1 compound, more preferably alprostadil, and the S-nitrosothiol compound is preferably S-nitrosoglutathione. The invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing cerebrovascular disorders, cardiovascular disorders, benign prostatic hyperplasia (BPH), glaucoma, peptic ulcers or for inducing abortions.

    专利号:US-8017776-B2
    优先权日:2003-07-15
    标题 :Methods for synthesis of acyloxyalkyl compounds
    发明人:BHAT LAXMINARAYAN; GALLOP MARK A
    权利人:XENOPORT INC
    摘要:Disclosed herein are methods for synthesizing 1-(acyloxy)-alkyl prodrug derivatives of drugs through oxidation of 1-acyl-alkyl derivatives of drugs under anhydrous reaction conditions. The methods typically proceed stereospecifically, in high yield, do not require the use of activated intermediates and/or toxic compounds and are readily amenable to scale-up.

    专利号:US-8143437-B2
    优先权日:2002-02-19
    标题:Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
    发明人:GALLOP MARK A; XIANG JIA-NING; YAO FENMEI; BHAT LAXMINARAYAN; ZHOU CINDY X
    权利人:GALLOP MARK A; XIANG JIA-NING; YAO FENMEI; BHAT LAXMINARAYAN; ZHOU CINDY X; XENOPORT INC
    摘要:The present invention provides a method for synthesizing 1-(acyloxy)-alkyl derivatives from 1-acyl-alkyl derivatives, which typically proceeds stereospecifically, in high yield, does not require the use of activated intermediates and/or toxic compounds and is readily amendable to scale-up. The current invention also provides 1-acyl-alkyl derivatives of known drug components and methods for synthesizing these 1-acyl-alkyl derivatives.

    专利号:US-2005239725-A1
    优先权日:2002-02-19
    标题:Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof

    专利号:US-2005070715-A1
    优先权日:2003-07-15
    标 题:Methods for synthesis of acyloxyalkyl compounds

    专利号:US-7560483-B2
    优先权日:2002-02-19
    标题 :Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: A multicentre randomized comparative clinical trial of 200 mg RU486 (mifepristone) single dose followed by either 5 mg 9-methylene PGE(2) gel (meteneprost) or 600 microg oral PGE(1) (misoprostol) for termination of early pregnancy within 28 days of missed menstrual period. ICMR Task Force Study. Indian Council of Medical Research. Contraception. 2000 Sep;62(3):125-30. French. French.

    合成参考文献


    参考文献:10.1016/0020-7292(82)90026-1
    摘要:Shapiro AG, Lasseter K, Cobiella A, Domenzain M. Intravaginal administration of 9-deoxo-9-methylene-16,16-dimethyl PGE2for cervical dilation prior to suction curettage. International Journal of Gynecology & Obstetrics. 1982 Apr;20(2):137–40. doi: 10.1016/0020-7292(82)90026-1.
    参考文献:10.1016/s0090-9556(25)08014-6
    摘要:Steffenrud S. Metabolism of 9-deoxo-16,16-dimethyl-9-methylene prostaglandin E2 in humans. Drug Metabolism and Disposition. 1983 May;11(3):255–65. doi: 10.1016/s0090-9556(25)08014-6.
    参考文献:10.1016/s0015-0282(16)49089-8
    摘要:Wallach EE, Castadot RG. Pregnancy termination: techniques, risks, and complications and their management. Fertility and Sterility. 1986 Jan;45(1):5–17. doi: 10.1016/s0015-0282(16)49089-8.
    摘要:Friedli A, De Grandi P. [Preoperative dilatation of the cervix uteri by vaginal application of 9-deoxo-16, 16-dimethyl-9-methylene PGE2 in pregnancy interruption during the 1st trimester. Double-blind clinical study]. J Gynecol Obstet Biol Reprod (Paris). 1986;15(2):215–21.
    参考文献:10.1007/bf00583936
    摘要:Christensen N, Bygdeman M, Greén K, Jonasson H, Rundgren M, Wallin C, Vesterqvist O, Leksell LG. The prostaglandin-analogue-9-deoxo-16,16-dimethyl-9-methylene-PGE2 inhibits the antidiuretic effect of vasopressin (AVP) in the conscious sheep. Pflügers Archiv - European Journal of Physiology. 1984 Dec;402(4):360–3. doi: 10.1007/bf00583936.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知